Gynecomastia Management: An Evolution and Refinement in Technique at UT Southwestern Medical Center

Steven H. Bailey, MD*
Dax Guenther, MD†
Fadi Constantine, MD*
Rod J. Rohrich, MD*

Summary: Gynecomastia is a benign proliferation of male breast glandular tissue. Gynecomastia can affect men at any stage of life. Traditional treatment options involved excisional surgeries with periareolar or T-shaped scars, which can leave more visible scars on the chest. The technique presented represents a technique used by the senior author, which relies on ultrasonic liposuction and pull-through technique to remove breast tissue. A retrospective chart review was performed, including all patients who were treated, from 2000 to 2013 by the senior author, for gynecomastia. A deidentified database was created to record patient characteristics, including age, height, weight, ptosis, stage of gynecomastia, and gynecomastia classification. Surgical approaches, complications, and revisions were also recorded. Our experience includes 75 patients with all grades of gynecomastia from 2000 to 2013. These cases span the evolution of our technique to include direct pull-through excision with ultrasound-assisted liposuction. The distribution of the grades I, II, III, and IV ptosis was 30.6%, 36%, 22.6%, and 10.6% respectively. There were no complications in this series. Only one patient with grade III ptosis required revision surgery. This technique provides a safe and aesthetically pleasing way to treat gynecomastia with a low need for revision. (Plast Reconstr Surg Glob Open 2016;4:e734; doi: 10.1097/GOX.0000000000000675; Published online 13 June 2016.)

Gynecomastia is a benign proliferation of male breast glandular tissue, which may present as unilateral or bilateral. Its prevalence ranges from 90% in neonates to 50% to 70% in adolescents and elderly men. The diagnosis can typically be made with a careful history and physical exam. The essential goals of this study are to differentiate gynecomastia from cancer.

The first step is to determine on physical examination if the enlarged breast tissue is carcinoma. Breast carcinoma is typically unilateral, firm, nontender and may be located either behind or outside of the nipple areola complex (NAC). Additionally, cancer may have concomitant skin dimpling, nipple retraction, and nipple discharge or bleeding. In contrast, gynecomastia and pseudogynecomastia are typically bilateral, not hard, and are in line with the NAC. Patients with gynecomastia will have a disk of fibrous tissue behind the NAC, which patients with pseudogynecomastia do not have. If carcinoma cannot be ruled out on physical examination, imaging should be used and suspicious masses should be biopsied.

A myriad of medical treatment options are available to identify the type of gynecomastia (physiologic, lipid-mediating, endocrine, etc.). Excisional surgery is still considered the gold standard for gynecomastia treatment. Although simple suction-assisted lipectomy is often used as a sole procedure, it is limited in the treatment of moderate to large breast volumes. The limitations of these procedures include the need for surgical excision of glandular tissue, which may leave more visible scars on the chest. The technique presented represents a technique used by the senior author, which relies on ultrasonic liposuction and pull-through technique to remove breast tissue. A retrospective chart review was performed, including all patients who were treated, from 2000 to 2013 by the senior author, for gynecomastia. A deidentified database was created to record patient characteristics, including age, height, weight, ptosis, stage of gynecomastia, and gynecomastia classification. Surgical approaches, complications, and revisions were also recorded. Our experience includes 75 patients with all grades of gynecomastia from 2000 to 2013. These cases span the evolution of our technique to include direct pull-through excision with ultrasound-assisted liposuction. The distribution of the grades I, II, III, and IV ptosis was 30.6%, 36%, 22.6%, and 10.6% respectively. There were no complications in this series. Only one patient with grade III ptosis required revision surgery. This technique provides a safe and aesthetically pleasing way to treat gynecomastia with a low need for revision.

Disclosure: Rod J. Rohrich, MD is a volunteer member of the Allergan Alliance for the Future of Aesthetics and receives instrument royalties from Eriem Surgical, Inc and book royalties from Taylor and Francis Publishing. The other authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

Supplemental digital content is available for this article. Clickable URL citations appear in the text.
pathologic, pharmacologic, and idiopathic) in proliferative phase (Tables 2 and 3). These treatments range from testosterone (in patients without hypogonadism), dihydrotestosterone, danazol, clomiphene citrate, testolactone, and raloxifene and tamoxifen. However, if gynecomastia is in its fibrous phase, or present for more than 1 year, it is unlikely to regress. In such circumstances, surgery is the best option for cosmetic improvement.

Surgical treatment historically has been subcutaneous mastectomy with or without direct skin incision, which was very successful at removing the subareolar fibrous disk but often left unacceptable scars. Rohrich et al introduced a step-wise approach employing a new classification system using ultrasound-assisted liposuction (UAL; Table 4).

UAL has several advantages in the treatment of gynecomastia. UAL breaks up the dense fibroconnective tissue of the male breast more efficiently than suction-assisted lipectomy (SAL), and at higher energy settings, UAL has the capacity to remove the dense parenchymal tissue that SAL leaves behind. Rohrich et al introduced a step-wise approach employing a new classification system using ultrasound-assisted liposuction (UAL; Table 4).

Table 1. Pseudogynecomastia Gynecomastia Breast Cancer

| Characteristics | Pseudogynecomastia | Gynecomastia | Breast Cancer |
|-----------------|--------------------|--------------|--------------|
| NAC             | Soft               | Firm disk    | Firm ± associated with the NAC |
| Unilateral      | No                 | Yes*         | Yes          |
| Bilateral       | Yes                | Yes          | No           |
| Bleeding        | No                 | No           | Yes*         |
| Nipple discharge| No                 | No           | Yes*         |
| Nipple retraction| No                | No           | Yes*         |

* +/–

Table 2. Categorization of Gynecomastia

| Categories of Gynecomastia | History Clues                                                                 | Physical Examination Clues                                                                 | Treatment Course                                                                 |
|----------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Physiologic                | Usually peaks in neonatal period, prepubertal/pubertal, or elderly age group. | Normal scrotum                                                                          | Usually self-limited. If gynecomastia persists into the fibrous phase, surgery may be required |
| Pharmacologic              | Illicit drug use, prescription drug use (common drugs are listed in Table 3) | Normal scrotum                                                                          | Stop inciting drug. If gynecomastia persists or only partially regresses, treat with surgery |
| Pathologic                 | Visual changes/ headache (pituitary tumor), cough (bronchogenic tumor), mumps, trauma (gonadal failure) | Obesity (peripheral conversion), scrotal mass (testicular tumors), loss of male pattern hair distribution (gonadal failure), undescended testis, stigmata of liver disease, enlarged thyroid (hyperthyroidism) | Treat underlying cause, surgical treatment indicated if gynecomastia does not regress or if gynecomastia in fibrous phase |
| Idiopathic                 | NA                                                                            | NA                                                                                       | Treat surgically                                                                  |

NA, not available.

Method

Chart Review

A retrospective chart review was performed in accordance with the amended Declaration of Helsinki.
and was approved by the institutional review board at our institution. Patients with gynecomastia treated with the pull-through technique and UAL from 2000 to 2013 were reviewed. A de-identified database was created to record the patients’ characteristics including age, height, weight, ptosis, stage of gynecomastia, and gynecomastia classification. Surgical approaches, complications, and revisions were also recorded.

**Surgical Technique: UAL and Pull-Through Excision Technique**

Markings are made in the preoperative holding area with the patient sitting. The inframammary fold is marked. The adherent zones in the upper outer quadrants are marked to be avoided. The areas of excess tissue around and behind the nipple are also marked (Fig. 1). The patients are given general anesthesia and positioned supine with the arms abducted. A small 3- to 4-mm stab incision is made in the lateral inframammary fold and infiltrations of wetting solution performed in the “superwet” fashion (a 1:1 ratio of infiltrate to estimated aspirate, \( \text{http://links.lww.com/PRSGO/A220} \)).

**UAL, direct excision ± delayed skin resection**

**Table 4. Classification and Management of Gynecomastia**

| Classification | Management |
|----------------|------------|
| Grade I, minimal hypertrophy (<250 g) without ptosis | UAL ± direct excision |
| Primarily glandular | UAL ± direct excision |
| Primarily fibrous | UAL ± direct excision |
| Grade II, moderate hypertrophy (250–500 g) without ptosis | UAL + direct excision |
| Primarily glandular | UAL + direct excision |
| Primarily fibrous | UAL + direct excision |
| Grade III, severe hypertrophy (>500 g) with grade I ptosis | UAL, direct excision ± delayed skin resection |
| Grade IV, severe hypertrophy (>500 g) with grade II or III ptosis | UAL, direct excision ± delayed skin resection |

**Video Graphic 1.** See video, Supplemental Digital Content 1, which demonstrates infiltrations of wetting solution performed in the “superwet” fashion (a 1:1 ratio of infiltrate to estimated aspirate, \( \text{http://links.lww.com/PRSGO/A220} \)).

**Video Graphic 2.** See video, Supplemental Digital Content 2, which demonstrates a UAL performed with an ultrasound generator, a 5-mm blunt-tip cannula or a 4-mm golf-tee cannula, and a surgical aspirator for evacuation, \( \text{http://links.lww.com/PRSGO/A221} \).

**Fig. 1.** The inframammary fold and the areas of excess tissue around and behind the nipple are also marked along with the adherent zones in the upper outer quadrants.
the nondominant hand guides the cannula through the subdermal layer. This addresses the dense fibrous tissue and allows for skin retraction. The periphery is feathered and the inframammary fold disrupted. This allows excess skin to re-drape and create a more gradual transition of the breast to the abdomen. The adherent zone marked preoperatively is suctioned minimally, if at all. SAL is then performed using a 3.7-mm cannula for evacuation and final contouring (See video, Supplemental Digital Content 3, which demonstrates an SAL performed using a 3.7-mm cannula for evacuation and final contouring, http://links.lww.com/PRSGO/A222). SAL proceeds from the deep to intermediate layer until endpoints are reached.

After evacuation is complete, a Kocher clamp is introduced through the stab incision (Fig. 2) and the residual subareolar dense tissue is grasped with a clamp (Fig. 3) pulled through the incision, and directly excised (Fig. 4). Once the appropriate contour is achieved, the lateral inframammary incisions are closed with a single 5-0 plain gut suture.

The chest wall is dressed with an abdominal pad and a double layer of topifoam (Fig. 5), and a compressive vest is worn for 4 weeks continuously followed by 4 weeks of nighttime wear only.

RESULTS

Our experience includes 75 patients with all grades of gynecomastia from 2000 to 2013. These cases span the evolution of our technique to include direct pull-through excision with UAL.

As stated previously, patients with all grades of gynecomastia were included. The specific distribution is as follows: 23 (30.6%) with grade I, 27 (36%) with grade II, 17 (22.6%) with grade III, and 8 (10.6%) with grade IV.

There were no complications in this series. Only one patient required revision surgery. He initially
presented with grade III gynecomastia and required a return to the operating room for minor subareolar UAL suction and direct periareolar excision to obtain an optimum result.

**DISCUSSION**

The understanding of the etiology and pathophysiology of gynecomastia continues to slowly expand. Diagnostic algorithms have been developed to increase the efficiency and limit the use of unnecessary and costly diagnostic studies in select patient subgroups. Despite the advances in medical treatment of gynecomastia, surgery still remains the only effective treatment for patients with fibrous gynecomastia.

The senior author’s classification system for the surgical treatment of gynecomastia is based on the amount and character of the hypertrophied breast tissue and the degree of ptosis Table 4. The initial report of 61 patients treated from 1987 to 2000 demonstrated that UAL was effective for all grades. No further treatment was needed for patients with grade I or II gynecomastia. Forty-two percent of patients with grade III or IV gynecomastia required staged excision of remaining breast tissue and skin to obtain optimum results. As originally designed in the algorithm, if removal of redundant skin and/or resistant breast tissue was still required after UAL, a stage excision was planned for 6 to 9 months. This was to allow for maximal skin retraction and healing so that the magnitude of the eventual excision was minimized.

Since this publication, UAL has become widely accepted as the treatment for gynecomastia. Recently, however, there have been reports of combining UAL and subareolar excision techniques within the same setting. Excision techniques have included direct excision, "pull through" from small incisions, and the use of cartilage shavers. There have also been recent reports of laser-assisted liposuction to treat gynecomastia, but the experience remains limited and its utility continues to be defined.

The evolution of our technique has paralleled these advances. The recent experience from our institution includes 75 patients treated simultaneously with UAL and direct excision with no complications and a single re-operation. This has demonstrated that this technique can be safely accomplished with good results. This represents an evolution from the original treatment algorithm of staging direct excision of 6 to 9 months after UAL. Furthermore, our results are in agreement with that of similar techniques combining liposuction with direct excision by other groups. Hammond et al reported treating 15 patients with no long-term complications and no re-operations. Lista and Ahmad reported treating 96 patients with 1.0% complications (2 seromas) and no revisions.

UAL provides the advantages of minimal scarring and efficient removal of both glandular and fibrotic breast tissue. A considerable amount of skin retraction is seen in patients with grade III and IV gynecomastia, often obviating the need for additional procedures to remove excess skin. Although not
necessary for the majority of patients in our cohort, if residual skin excess necessitates additional tailoring with mastopexy techniques, we recommend the procedure be performed in a delayed fashion at 6 to 9 months. By delaying excision, the NAC is able to revascularize via a central pedicle, thereby allowing incision and mild undermining of surrounding breast flaps.

With these additional findings regarding the surgical management of gynecomastia, we still advocate grade-directed treatment, but have updated our treatment algorithm to include simultaneous UAL and direct excision via the pull-through technique obviating the need for a periareolar incision. The only exception and a contraindication for this technique is a patient with Klinefelter syndrome. These patients have a 60× greater risk of developing breast cancer (1:400 to 1:1,000) and thus should have a mastectomy to allow for complete removal and complete pathologic evaluation.

CONCLUSIONS

The evaluation of gynecomastia can be complex, but a step-wise approach that starts with careful history taking and physical examination simplifies the process. Extensive laboratory testing and diagnostic imaging may be avoided in certain subgroups. Although medical therapies have been shown to be effective in new-onset florid gynecomastia, the treatment of chronic fibrous gynecomastia remains surgical. Evolution of the treatment of gynecomastia to include liposuction and direct subareolar pull-through excision is a safe and effective treatment for the vast majority of patients with gynecomastia. Minimally invasive techniques through minimal incisions offer fast recovery, low complication rates, excellent cosmesis, and high tolerance.

Rod J. Rohrich, MD
Department of Plastic Surgery
UT Southwestern Medical Center
1801 Inwood Rd.
Dallas, TX 75390
E-mail: Rod.Rohrich@utsouthwestern.edu

REFERENCES

1. McKiernan JF, Hull D. Breast development in the newborn. Arch Dis Child. 1981;56:525–529.
2. Nydick M, Bustos J, Dale JH Jr, et al. Gynecomastia in adolescent boys. JAMA 1961;178:449–454.
3. Sher ES, Migeon CJ, Berkovitz GD. Evaluation of boys with marked breast development at puberty. Clin Pediatr (Phila). 1998;37:367–371.
4. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48:338–340.
5. Ley SJ. Cardiac surgery in an era of antiplatelet therapies: generating new evidence. Reflect Nurs Leadersh. 2002;28:35.
6. Carlson HE. Gynecomastia. N Engl J Med. 1980;303:795–799.
7. Niewoechner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984;77:633–638.
8. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol. 1994;21:579–587.
9. Williams MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med. 1963;34:103–112.
10. Braunstein GD. Gynecomastia. N Engl J Med. 2007;357:1229–1237.
11. Deepinder F, Braunstein GD. Gynecomastia: incidence, causes and treatment. Expert Rev Endocrinol Metabol. 2011;6:723–730.
12. Alagatranam TT. Idiopathic gynecomastia treated with tamoxifen: a preliminary report. Clin Ther. 1987;9:483–487.
13. Khan HN, Rampaul R, Blamey RW. Management of physiologic gynaecomastia with tamoxifen. Breast 2004;13:61–65.
14. Rohrich RJ, Ha RY, Kenkel JM, et al. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg. 2003;111:909–923; discussion 924–925.
15. Rohrich RJ, Beran SJ, Kenkel JM, et al. Extending the role of liposuction in body contouring with ultrasound-assisted liposuction. Plast Reconstr Surg. 1998;101:1090–1102; discussion 1117.
16. Hammond DC. Surgical correction of gynecomastia. Plast Reconstr Surg. 2009;124:61e–68e.
17. Petty PM, Solomon M, Buchel EW, et al. Gynecomastia: evolving paradigm of management and comparison of techniques. Plast Reconstr Surg. 2010;125:1301–1308.
18. Hodgson EL, Fruhstorfer BH, Malata CM. Ultrasonic liposuction in the treatment of gynecomastia. Plast Reconstr Surg. 2005;116:646–653; discussion 654.
19. Ratnam BV. A new classification and treatment protocol for gynecomastia. Aesthet Surg J. 2009;29:26–31.
20. Lista F, Ahmad J. Power-assisted liposuction and the pull-through technique for the treatment of gynecomastia. Plast Reconstr Surg. 2008;121:740–747.
21. Benito-Ruiz J, Raigosa M, Manzano M, et al. Assessment of a suction-assisted cartilage shaver plus liposuction for the treatment of gynecomastia. Aesthet Surg J. 2009;29:302–309.
22. Prado AC, Castillo PF. Minimal surgical access to treat gynecomastia with the use of a power-assisted arthroscopic-endoscopic cartilage shaver. Plast Reconstr Surg. 2005;115:939–942.
23. Ramon Y, Fodor L, Peled IJ, et al. Multimodality gynecomastia repair by cross-chest power-assisted superficial liposuction combined with endoscopic-assisted pull-through excision. Ann Plast Surg. 2005;55:591–594.
24. Bracaglia R, Fortunato R, Gentileschi S, et al. Our experience with the so-called pull-through technique combined with liposuction for management of gynecomastia. Ann Plast Surg. 2004;53:22–26.
25. Apfelberg DB, Rosenthal S, Hunstad JP, et al. Progress report on multicenter study of laser-assisted liposuction. Aesthetic Plast Surg. 1994;18:259–264.
26. Wollina U, Goldman A, Berger U, et al. Esthetic and cosmetic dermatology. Dermatol Ther. 2008;21:118–130.
27. Goldman A, Wollina U. Subdermal Nd:YAG laser for axillary hyperhidrosis. Dermatologic Surg. 2008;34:756–762.
28. Webster JP. Mastectomy for gynecomastia through a semicircular intra-areolar incision. Ann Surg 1946;124:557–575.

29. Lynch RC. An operation for correction of gynecomastia through an areolar incision. Plast Reconstr Surg (1946). 1954;13:412–418.

30. Giacobine JW, Scarle NB. Management of gynecomastia. Am J Surg 1961;102:395–402.

31. Von Kessel F, Pickrell KL, Hugger WE, et al. Surgical treatment of gynecomastia: an analysis of 275 cases. Ann Surg 1963;157:142–151.

32. Pitanguy I. Transareolar incision for gynecomastia. Plast Reconstr Surg 1966;38:414–419.

33. Letterman G, Schurter M. The surgical correction of massive gynecomastia. Plast Reconstr Surg 1972;49:259–262.

34. Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg 1973;51:48–52.

35. Wray RC Jr, Hoopes JE, Davis GM. Correction of extreme gynecomastia. Br J Plast Surg 1974;27:39–41.

36. Eade GG. The radial incision for gynecomastia excisions. Plast Reconstr Surg 1974;54:495–497.

37. Bretteville-Jensen G. Surgical treatment of gynecomastia. Br J Plast Surg 1975;28:177–180.

38. Artz S, Lehman JA Jr. Surgical correction of massive gynecomastia. Arch Surg 1978;113:199–201.

39. Balch CR. A transaxillary incision for gynecomastia. Plast Reconstr Surg 1978;61:13–16.

40. Davison BA. Concentric circle operation for massive gynecomastia to excise the redundant skin. Plast Reconstr Surg. 1979;63:350–354.

41. Huang TT, Hidalgo JE, Lewis SR. A circumareolar approach in surgical management of gynecomastia. Plast Reconstr Surg 1982;69:35–40.

42. Welsh F. Handlebar moustache breast reduction. Plast Reconstr Surg 1982;69:544–546.

43. Teimourian B, Perlman R. Surgery for gynecomastia. Plast Reconstr Surg 1984;73:155–157.

44. Lewis CM. Lipoplasty: treatment for gynecomastia. Aesthetic Plast Surg 1985;9:287–292.

45. Courtiss EH. Gynecomastia: analysis of 139 patients and current recommendations for treatment. Plast Reconstr Surg. 1987;79:740–753.

46. Freiberg A, Hong C. Apple-coring technique for severe gynecomastia. Can J Surg 1987;30:57–60.

47. Rosenberg GJ. Gynecomastia: suction lipectomy as a contemporary solution. Plast Reconstr Surg 1988;70:379–386.

48. Abramowitz DJ, Bollen AM. Liposuction through an axillary incision for treatment of gynecomastia. Aesthetic Plast Surg. 1989;13:85–89.

49. Abramowitz DJ, Bollen AM. Axillary approach for gynecomastia liposuction. Aesthetic Plast Surg. 1994;18:265–268.

50. Aiache AE. Surgical treatment of gynecomastia in the body builder. Plast Reconstr Surg. 1989;83:61–66.

51. Ward CM, Khalid K. Surgical treatment of grade III gynecomastia. Ann R Coll Surg Engl. 1989;71:226–228.

52. Becker H. The treatment of gynecomastia without sharp excision. Ann Plast Surg 1990;24:380–383.

53. Mladick RA. Gynecomastia. Liposuction and excision. Clin Plast Surg 1991;18:815–822.

54. Rigg BM. Morselization suction: a modified technique for gynecomastia. Plast Reconstr Surg 1991;88:159–160.

55. Brenner P, Berger A, Schneider W, et al. Male reduction mammoplasty in serious gynecomastias. Aesthetic Plast Surg 1992;16:325–330.

56. Smadl F, Kleppe G, Amland PF, et al. Surgical treatment of gynecomastia. Five years’ experience with liposuction. Scand J Plast Reconstr Surg Hand Surg. 1994;28:123–130.

57. Kornstein AN, Cinelli PB. Inferior pedicle reduction technique for larger forms of gynecomastia. Aesthetic Plast Surg 1992;16:331–335.

58. Murphy TP, Ehrlichman RJ, Seckel BR. Nipple placement in simple mastectomy with free nipple grafting for severe gynecomastia. Plast Reconstr Surg. 1994;94:818–825.

59. Reyes R, Zicchi S, Hamed H, et al. Surgical correction of gynecomastia in bodybuilders. Br J Clin Pract. 1995;49:177–179.

60. Rosenberg GJ. A new cannula for suction removal of parenchymal tissue of gynecomastia. Plast Reconstr Surg 1994;94:548–551.

61. Morselli PG. “Pull-through”: a new technique for breast reduction in gynecomastia. Plast Reconstr Surg 1996;97:450–454.

62. Botta SA. Alternatives for the surgical correction of severe gynecomastia. Aesthetic Plast Surg. 1998;22:65–70.

63. Colombo-Benkmann M, Buse B, Stern J, et al. Surgical therapy of gynecomastia and its results. Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1282–1284.

64. Hamas RS, Williams CW. A sharp cutting liposuction cannula for gynecomastia. Aesthet Surg J. 1998;18:261–265.

65. Gingrass MK, Schemer MA. The treatment of gynecomastia with ultrasound-assisted lipolysis. Semin Plast Surg 1999;12:101–112.

66. Ohyama T, Takada A, Fujikawa M, et al. Endoscopy-assisted transaxillary removal of glandular tissue in gynecomastia. Ann Plast Surg 1998;40:62–64.

67. Peters MH, Vastine V, Knox L, et al. Treatment of adolescent gynecomastia using a bipedicle technique. Ann Plast Surg 1998;40:241–245.

68. Smoot EC. Eccentric skin resection and purse-string closure for skin reduction with mastectomy for gynecomastia. Ann Plast Surg 1998;41:378–383.

69. Park AJ, Lamberty BG. Gynaecomastia: have Webster’s lessons been ignored? J R Coll Surg Edinb. 1998;43:89–92.

70. Chiu DT, Siegel HW. The pinwheel technique: an adjunct to the periareolar approach in gynecomastia resection. Ann Plast Surg 1999;42:465–469.

71. Gasperoni C, Salgarello M, Gasperoni P. Technical refinements in the surgical treatment of gynecomastia. Ann Plast Surg 2000;44:455–458.

72. Ersek RA, Schaeferle M, Beckham PH, et al. Gynecomastia: a clinical review. Aesthet Surg J. 2000;20:381–386.

73. Persichetti P, Berloco M, Casadei RM, et al. Gynecomastia and the complete circumareolar approach in the surgical management of skin redundant. Plast Reconstr Surg. 2001;107:948–954.

74. Steele SR, Martin MJ, Place RJ. Gynecomastia: complications of the subcutaneous mastectomy. Ann Surg 2002;286:210–213.

75. Fruhstorfer BH, Malata CM. A systematic approach to the surgical treatment of gynaecomastia. Br J Plast Surg. 2003;56:237–246.

76. Wiesman IM, Lehman AJr, Parker MG, et al. Gynecomastia: an outcome analysis. Ann Plast Surg. 2004;53:97–101.

77. Walden JL, Schmid RP, Blackwell SJ. Cross-cest lipoplasty and surgical excision for gynecomastia: a 10-year experience. Aesthet Surg J. 2004;24:216–223.
80. Babigian A, Silverman RT. Management of gynecomastia due to use of anabolic steroids in bodybuilders. *Plast Reconstr Surg* 2001;107:240–242.
81. Mladick RA. Continuing education: gynecomastia. *Aesthet Surg J* 2004;24:471–479.
82. Durani P, McCulley SJ. Transareolar and H-incisions for the surgical treatment of gynecomastia. *Plast Reconstr Surg* 2007;119:1387–1388.
83. Haddad Filho D, Arruda RG, Alonso N. Treatment of severe gynecomastia (grade III) by resection of periareolar skin. *Aesthet Surg J* 2006;26:669–673.
84. Ratnam BV. A new classification and treatment protocol for gynecomastia. *Aesthet Surg J* 2009;29:26–31.
85. Prado AS, Castillo P. Gynecomastia: evolving paradigm of management and comparison of techniques. *Plast Reconstr Surg* 2010;126:2291–2292; author reply 2292.